Citation Impact
Citing Papers
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Membrane Vesicles: an Overlooked Component of the Matrices of Biofilms
2006
Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
1988
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
2015
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres
2002 StandoutNobel
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
1999 Standout
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
1989
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy
1991
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Relation between dissolution profiles and toxicity of cisplatin-loaded microspheres
2002 StandoutNobel
Physiological concentrations of purines and pyrimidines
1994 Standout
Treatment of Malignant Pleural Effusions with Doxorubicin Hydrochloride-Containing Poly(L-Lactic Acid) Microspheres
1991
Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice
2002 StandoutNobel
Targeting Ferroptosis to Iron Out Cancer
2019 Standout
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Recent advances in removing phosphorus from wastewater and its future use as fertilizer (1997–2003)
2004 Standout
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
1992
Thymoquinone: Potential cure for inflammatory disorders and cancer
2011 Standout
Management of malignant pleural mesothelioma: a critical review
2000
Paclitaxel (Taxol)
1995 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatment
1990
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Cancer of the Ovary
1993
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Chemotherapy in malignant mesothelioma: a review
1991
Molecular mechanisms of cisplatin resistance
2011 Standout
Experimental and clinical status of intraperitoneal chemotherapy
1990
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Biology of Natural Killer Cells
1989 Standout
Biofilms: an emergent form of bacterial life
2016 Standout
Toxicity of platinum compounds
2003
Chemotherapy and the war on cancer
2005 Standout
The biofilm matrix
2010 Standout
Peritonectomy Procedures
1995 Standout
Nucleoside and nucleobase transport in animal cells
1988
Novel applications of red mud as coagulant, adsorbent and catalyst for environmentally benign processes
2008 Standout
Mechanisms of relapse for colorectal cancer: Implications for intraperitoneal chemotherapy
1991
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines
1998
Cisplatin Overdose
2009
Chemotherapy in malignant pleural mesothelioma. A review.
1996
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Pleurectomy/Decortication and Adjuvant Therapy for Malignant Mesothelioma
1993
Hypersensitivity reactions from taxol.
1990 Standout
Management of malignant pleural effusions
2001 Standout
Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions
2015 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
1994
Recent advances on chitosan-based micro- and nanoparticles in drug delivery
2004 Standout
Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy
2017
Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
2001
Paclitaxel and its formulations
2002 Standout
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
1996
Sclerotherapy for Malignant Pleural Effusions
1998
Modulation of cis-diamminedichloroplatinum(II) resistance: a review
1992
WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach
1993
Advances in Malignant Mesothelioma
2005 Standout
High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation
1989
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
1994
Controlled cisplatin delivery system using poly(d,l-lactic acid]
1992
Cancer of the Ovary
2004 Standout
Chitosan microspheres as a potential carrier for drugs
2004 Standout
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
2010 StandoutNobel
Changes in Cisplatin Delivery Due to Surface-Coated Poly (Lactic Acid)–Poly(∊-Caprolactone)Microspheres
2002
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Intraperitoneal Therapy for Peritoneal Cancer
2010
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
2011 Standout
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
2004 Standout
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms
1989
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Ovarian cancer: new clinical approaches
1991
INTRAPERITONEAL CHEMOTHERAPY
1994
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
2023 StandoutNobel
Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Gastrointestinal Origin
2000
Intraperitoneal therapy in the management of ovarian carcinoma.
1990
Biodegradation and biocompatibility of PLA and PLGA microspheres
1997 Standout
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Platinum resistance: Laboratory findings and clinical implications
1993
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
2003 Standout
Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
2015 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Biological Functions and Biogenesis of Secreted Bacterial Outer Membrane Vesicles
2010 Standout
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
New Therapies for Ovarian Cancer
1992
Intrapleural Chemotherapy Without Pleurodesis for Malignant Pleural Effusions
1994
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
1999
Works of Stephen Cleary being referenced
Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.
1988
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
1987
Acid-stimulated phosphate uptake by activated sludge microorganisms under aerobic laboratory conditions
2001
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
1986
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.
1985
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection
1985
Hypomagnesemia Following High-Dose Intracavitary Cisplatin with Systemically Administered Sodium Thiosulfate
1986
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.
1987
Phase I trial of combination therapy of cancer with N-phosphanacetyl-L-aspartic acid and dipyridamole
1987
Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.
1986
Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients.
1988
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma
1986
Cisplatin and cytarabine administered intrapleurally as treatment of malignant pleural effusions
1985
High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity
1985